<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00410631</url>
  </required_header>
  <id_info>
    <org_study_id>GPOH-NB2004</org_study_id>
    <secondary_id>CDR0000517312</secondary_id>
    <secondary_id>EU-20661</secondary_id>
    <nct_id>NCT00410631</nct_id>
  </id_info>
  <brief_title>Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma</brief_title>
  <official_title>NB2004 Trial Protocol for Risk Adapted Treatment of Children With Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor
      cells, either by killing the cells or by stopping them from dividing. Giving combination
      chemotherapy may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill
      tumor cells. An autologous stem cell transplant may be able to replace blood-forming cells
      that were destroyed by chemotherapy and radiation therapy. This may allow more chemotherapy
      to be given so that more tumor cells are killed. Sometimes, after surgery, the tumor may not
      need more treatment until it progresses. In this case, observation may be sufficient. It is
      not yet known whether observation is more effective than combination chemotherapy, radiation
      therapy, and/or autologous stem cell transplant in treating neuroblastoma.

      PURPOSE: This randomized phase III and phase IV trial is studying observation, combination
      chemotherapy, radiation therapy, and/or autologous stem cell transplant to compare how well
      they work in treating young patients with neuroblastoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the event-free survival (EFS) of younger patients with newly diagnosed
           neuroblastoma categorized in the low-risk group (LRG) who undergo observation only or
           receive combination chemotherapy.

        -  Compare the EFS rate in patients with neuroblastoma categorized in the medium-risk group
           (MRG) treated with combination induction therapy, maintenance therapy, and consolidation
           therapy with that of a historical control group.

        -  Compare the EFS in patients with neuroblastoma categorized in the high-risk group (HRG)
           treated with standard vs experimental induction therapy followed by autologous stem cell
           transplantation and consolidation therapy.

      Secondary

        -  Determine the locoregional EFS of patients in the LRG, MRG, or HRG.

        -  Determine the overall survival of these patients.

        -  Determine the extent of initial surgery, the extent or impact of best surgery, and
           surgery-related complications in these patients.

        -  Determine the time to transition to stage 4 disease in patients in the LRG or MRG.

        -  Determine the time to a locoregional event in patients in the LRG or HRG.

        -  Determine the time from diagnosis to an event in patients in the LRG.

        -  Determine the time from the beginning of regression to an adverse event in patients in
           the LRG.

        -  Determine the time to the beginning of primary tumor regression in patients in the LRG.

        -  Determine the time to the normalization of tumor markers in patients in the LRG.

        -  Determine the time to no evidence of disease in patients in the LRG with stage 4S
           disease.

        -  Assess the status of the primary tumor at 12 months and the best status of the primary
           tumor within 12 months in patients in the LRG.

        -  Determine the need for chemotherapy to control progression and the intensity of therapy
           required in patients in the LRG.

        -  Determine the acute and late side effects of external-beam radiotherapy in patients in
           the MRG or HRG.

        -  Determine the response to induction therapy in patients in the HRG.

        -  Assess early response after 2 courses of induction therapy in patients in the HRG.

        -  Determine the toxicity during induction courses 1 and 2 and the frequency of grade 3 or
           4 toxicity during induction therapy in patients in the HRG.

        -  Assess the efficacy of iodine I 131 metaiodobenzylguanidine (MIBG) therapy, in terms of
           activity and whole body dose, in patients in the HRG.

        -  Assess molecular markers (e.g., chromosome 1p, chromosome 11q, neuroblastoma gene chip)
           in these patients.

      OUTLINE: This is a prospective, historically controlled, randomized, open-label, multicenter
      study. Patients are stratified according to disease risk (low-risk vs medium-risk vs
      high-risk).

        -  Low-risk group: Patients undergo complete staging 3 months after initial surgery.
           Patients with no progression are observed for 12 months (for patients over 1 year of
           age) or until the end of the second year of life (for patients 1 year of age or
           younger). Patients with localized progression or threatening symptoms undergo N4
           chemotherapy comprising doxorubicin hydrochloride IV over 30 minutes and vincristine IV
           on days 1, 3, and 5 and cyclophosphamide IV over 30 minutes on days 1-7. Treatment
           repeats every 21 days for up to 4 courses. Patients are reassessed after each course of
           N4 chemotherapy. Patients achieving stable disease or tumor regression at any point
           discontinue N4 chemotherapy and undergo observation. Patients with persistent
           progressive disease after 4 courses of N4 chemotherapy proceed to treatment as in the
           medium-risk group. Patients who progress to stage 4 disease after initial surgery
           proceed to treatment as in the medium-risk group (for patients 1 year of age or younger
           and no indication of stage 4S disease) or high-risk group (for patients over 1 year of
           age).

        -  Medium-risk group: Patients receive induction therapy followed by maintenance therapy
           and consolidation therapy.

             -  Induction therapy: Patients* receive N5 chemotherapy comprising cisplatin IV
                continuously over 96 hours and etoposide phosphate IV continuously over 96 hours on
                days 1-4, vindesine IV over 1 hour on day 1, and filgrastim (G-CSF) subcutaneously
                (SC) beginning on day 9 and continuing until blood counts recover. Patients then
                receive N6 chemotherapy comprising vincristine IV over 1 hour on days 1 and 8,
                dacarbazine IV over 1 hour and ifosfamide IV continuously over 120 hours on days
                1-5, doxorubicin hydrochloride IV over 4 hours on days 6 and 7, and G-CSF beginning
                on day 10 and continuing until blood counts recover. Treatment repeats every 21
                days alternating between N5 and N6 chemotherapy for up to 6 total courses (3
                courses of N5 and N6 each). Patients then proceed to maintenance therapy.

      NOTE: *Patients under 6 months of age receive up to 4 courses of N4 chemotherapy (as in the
      low-risk group) instead of N5/N6 chemotherapy until they reach 6 months of age.

      Patients with active residual tumor after induction chemotherapy undergo external-beam
      radiotherapy (EBRT) for up to 25 fractions concurrently with maintenance chemotherapy.
      Secondary surgery for resection of the primary tumor is attempted after course 4 or 6 of the
      induction therapy and before EBRT.

        -  Maintenance therapy: Patients receive N7 chemotherapy comprising cyclophosphamide orally
           or IV over 1 hour on days 1-8. Treatment repeats every 21 days for up to 4 courses in
           the absence of disease progression or unacceptable toxicity.

        -  Consolidation therapy: Beginning 21 days after completion of maintenance therapy,
           patients receive oral isotretinoin 2-3 times daily on days 1-14. Treatment repeats every
           28 days for up to 6 courses in the absence of unacceptable toxicity. Patients then
           receive 3 additional courses after 3-months of rest.

             -  High-risk group: Patients receive induction therapy followed by autologous stem
                cell transplantation (ASCT) and consolidation therapy.

        -  Induction therapy: Patients 1 year of age and over are randomized to 1 of 2 treatment
           arms. Patients under 1 year of age do not undergo randomization; instead they are
           assigned to arm I.

             -  Arm I (standard): Patients* receive N5 and N6 chemotherapy as in induction therapy
                for the medium-risk group.

             -  Arm II (experimental): Patients receive N8 chemotherapy comprising topotecan
                hydrochloride IV continuously over 168 hours and cyclophosphamide IV over 1 hour on
                days 1-7, etoposide IV over 1 hour on days 8-10, and G-CSF SC beginning on day 12
                and continuing until blood counts recover. Treatment repeats every 21 days for 2
                courses. Patients then receive N5 and N6 chemotherapy as in induction therapy for
                the medium-risk group.

      In both arms, patients with active residual primary tumor after 6 courses of induction
      therapy undergo iodine I 131 metaiodobenzylguanidine (MIBG)** radiotherapy (before ASCT).
      Patients also undergo EBRT for up to 25 fractions after ASCT. Secondary surgery for resection
      of the primary tumor is attempted after course 4 or 6 of induction therapy and before
      radiotherapy.

      NOTE: *Patients under 6 months of age receive up to 4 courses of N4 chemotherapy (as in the
      low-risk group) instead of N5/N6 chemotherapy until they reach 6 months of age.

      NOTE: **Patients with MIBG-negative disease undergo EBRT only.

        -  Conditioning followed by ASCT: Patients receive melphalan IV over 30 minutes on days -8
           to -5, etoposide phosphate IV over 4 hours on day -4, and carboplatin IV over 1 hour on
           days -4 to -2. Patients undergo ASCT on day 0. Patients receive G-CSF SC beginning on
           day 2 and continuing until blood counts recover.

        -  Consolidation therapy: Beginning 30 days after ASCT, patients receive isotretinoin* as
           in consolidation therapy for the medium-risk group.

      NOTE: *Isotretinoin is discontinued during EBRT and restarted 1 week after completion of
      EBRT.

      After completion of study treatment, patients are followed periodically.

      PROJECTED ACCRUAL: A total of 642 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2004</start_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Locoregional EFS</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from diagnosis to transition to stage 4 disease, to death from disease, or to the last follow-up (if no transition to stage 4 disease is observed)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the beginning of primary tumor regression (in patients in the low-risk group [LRG])</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the normalization of tumor markers HVA and VMA in urine</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to no evidence of disease (in patients in the LRG with stage 4S disease)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of the primary tumor 12 months after diagnosis (LRG)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best status of the primary tumor within the first 12 months (LRG)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of chromosome 1p (unblinded) and status of chromosome 11q (blinded)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the extent of initial surgery (incomplete resection vs macroscopic complete resection) (LRG)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the extent of best surgery during protocol treatment (incomplete resection vs macroscopic complete resection)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery-related complications (i.e., bleeding, infection, intestinal obstruction, or other)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression and symptoms controlled after the first, second, third, and fourth N4 course (LRG)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression and symptoms not controlled after four N4 courses (LRG)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transition to stage 4 disease at any time (LRG)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and late side effects of external-beam radiotherapy (medium-risk group [MRG] and high-risk group [HRG])</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early response after 2 courses of induction therapy (N5 and N6 or two courses of N8) (HRG)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to induction therapy prior to conditioning therapy or after 280 days (HRG)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade of toxicity observed during induction therapy course 1 (N5 or N8) (HRG)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade of toxicity observed during induction therapy course 2 (N6 or N8) (HRG)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of grade 3 or 4 toxicity observed during the last 6 courses of induction therapy (3 courses of N5 and N6) (HRG)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity and whole body dose of radiotherapy</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">642</enrollment>
  <condition>Neuroblastoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isotretinoin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vindesine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iobenguane I 131</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of neuroblastoma by histology using tumor tissue or as evidenced by the
             presence of distinct neuroblastoma cells in the bone marrow AND elevated catecholamine
             metabolites (i.e., homovanillic acid [HVA] and vanillylmandelic acid [VMA]) in blood
             or urine

               -  Newly diagnosed disease (for patients in the low-risk group)

               -  Diagnosis from tumor tissue (for patients in the medium-risk group)

          -  Meets criteria for 1 of the following risk groups:

               -  Low-risk group

                    -  No MYCN amplification AND meets 1 of the following criteria:

                         -  Stage 1 disease

                         -  Stage 2 disease with no chromosome 1p deletion or imbalance

                         -  Stage 3 disease with no chromosome 1p deletion or imbalance (for
                            patients &lt; 2 years of age)

                         -  Stage 4S disease (for patients &lt; 1 year of age)

               -  Medium-risk group

                    -  No MYCN amplification AND meets 1 of the following criteria:

                         -  Stage 2 disease with chromosome 1p deletion or imbalance

                         -  Stage 3 disease with chromosome 1p deletion or imbalance

                              -  Any chromosome 1p status (for patients ≥ 2 years of age)

                         -  Stage 4 disease (for patients &lt; 1 year of age)

               -  High-risk group, meeting 1 of the following criteria:

                    -  Any stage disease with MYCN amplification

                         -  Any MYCN status (for patients ≥ 1 year of age)

        PATIENT CHARACTERISTICS:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

          -  No prior nephrectomy or other mutilating surgery as initial surgery (for patients in
             the low-risk group)

          -  No other concurrent anticancer therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Berthold, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kinderklinik - Universitaetsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>D-52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. Mertens, MD, PhD</last_name>
      <phone>49-241-809-222</phone>
      <email>rmertens@ukaachen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>DOH-86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Gnekow</last_name>
      <phone>49-821-400-3603</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum am Bamberg</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloeckel, MD</last_name>
      <phone>49-951-506-0</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bayreuth</name>
      <address>
        <city>Bayreuth</city>
        <zip>D-95445</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T. Rupprecht</last_name>
      <phone>49-921-400-6202</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>D-13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L. Wickmann, MD</last_name>
      <phone>49-30-9401-2353</phone>
      <email>lwickmann@berlin.helios-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite University Hospital - Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunter Henze</last_name>
      <phone>49-30-450-566-004</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhauus Bielfeld</name>
      <address>
        <city>Biefeld</city>
        <zip>33617</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>N. Jorch, MD</last_name>
      <phone>49-521-7727-8050</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinderklinik der Universitaet Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>D-53113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Udo Bode, MD</last_name>
      <phone>49-228-2873-3215</phone>
      <email>udo.bode@ukb.uni-bonn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum - Howedestrase</name>
      <address>
        <city>Braunschweig</city>
        <zip>38118</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-531-595-1222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>D-28205</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnulf Pekrun, MD, PhD</last_name>
      <phone>49-421-497-3656</phone>
      <email>arnulf.pekrun@klinikum-bremen-mitte.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allgemeinen Krankenhaus Celle Kinderklinik</name>
      <address>
        <city>Celle</city>
        <zip>29223</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Kirschstein, MD</last_name>
      <phone>49-241-809-222</phone>
      <email>martin.kirschstein@akh-celle.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>D-09116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krause, MD</last_name>
      <phone>49-371-3332-4124</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Frank, MD</last_name>
      <phone>49-8561-225-547</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Koeln gGmbH - Kinderkrankenhaus Riehl</name>
      <address>
        <city>Cologne</city>
        <zip>D-50735</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-221-8907-5243</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>Cologne</city>
        <zip>D-50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Berthold, MD</last_name>
      <phone>49-221-478-4380</phone>
      <email>frank.berthold@uk-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carl - Thiem - Klinkum Cottbus</name>
      <address>
        <city>Cottbus</city>
        <zip>D-03048</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Mobius, MD</last_name>
      <phone>49-355-462-336</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vestische Kinderklinik</name>
      <address>
        <city>Datteln</city>
        <zip>45704</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W. Andler, MD</last_name>
      <phone>49-2363-9750</phone>
      <email>w.andler@kinderklinik-datteln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Lippe - Detmold</name>
      <address>
        <city>Detmold</city>
        <zip>D-32756</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Wesseler, MD</last_name>
      <phone>49-5231-724-510</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund</name>
      <address>
        <city>Dortmund</city>
        <zip>D-44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Olscheswski, MD</last_name>
      <phone>49-231-9532-1721</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Suttorp, MD</last_name>
      <phone>49-351-458-5035</phone>
      <email>meinolf.suttorp@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaets - Frauenklinik, Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dilloo, MD</last_name>
      <phone>49-211-811-7680</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Duisburg</name>
      <address>
        <city>Duisburg</city>
        <zip>D-47055</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruef, MD</last_name>
      <phone>49-203-733-2421</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Erfurt</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Sauerbrey, MD</last_name>
      <phone>49-361-781-3702</phone>
      <email>asauerbrey@erfurt.helios-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaets - Kinderklinik</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W. Holter, MD</last_name>
      <phone>49-9131-853-3118</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Kremens, MD</last_name>
      <phone>49-201-723-2453</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe Universitaet</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Klingebiel, MD</last_name>
      <phone>49-69-6301-5243</phone>
      <email>thomas.klingebiel@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetskinderklinik - Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Niemeyer, MD</last_name>
      <phone>49-761-270-4552</phone>
      <email>charlotte.niemeyer@uniklinik-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinderklinik</name>
      <address>
        <city>Giessen</city>
        <zip>D-35385</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfred Reiter, MD</last_name>
      <phone>49-641-994-3400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>D-37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lothar Schweigerer, MD</last_name>
      <phone>49-551-396-210</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitats - Kinderklinik</name>
      <address>
        <city>Greiswald</city>
        <zip>17487</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James F. Beck, MD</last_name>
      <phone>49-3834-866-325</phone>
      <email>beck@uni-greifswald.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Halle</name>
      <address>
        <city>Halle</city>
        <zip>D-06097</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dieter Koerholz, MD</last_name>
      <phone>49-345-557-2911</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus St. Elisabeth und St. Barbara</name>
      <address>
        <city>Halle</city>
        <zip>D-06110</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G. Guenther, MD</last_name>
      <phone>49-345-213-4514</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Erttmann, MD</last_name>
      <phone>49-40-428-034-270</phone>
      <email>erttmann@uke.uni-hamburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinderkrankenhaus auf der Bult</name>
      <address>
        <city>Hannover</city>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>U. Hofmann, MD</last_name>
      <phone>49-511-811-5424</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Welte, MD</last_name>
      <phone>49-511-532-9123</phone>
      <email>welte.karl.h@mh-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaets-Kinderklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas E. Kulozik, MD, PhD</last_name>
      <phone>49-6221-562-311</phone>
      <email>andreas.kulozik@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SLK - Kliniken Heilbronn GmbH - Klinikum am Gesundbrunnen</name>
      <address>
        <city>Heilbronn</city>
        <zip>D-74064</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Full, MD</last_name>
      <phone>49-7131-493-702</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftskrankenhaus</name>
      <address>
        <city>Herdecke</city>
        <zip>58313</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Tautz, MD</last_name>
      <phone>49-233-0620</phone>
      <email>ctautz@yahoo.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert Graf</last_name>
      <phone>49-6841-162-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaets - Kinderklinik</name>
      <address>
        <city>Jena</city>
        <zip>D-07440</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Peron</last_name>
      <phone>49-3641-938-270</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaets - Kinderklinik</name>
      <address>
        <city>Jena</city>
        <zip>D-07745</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Zintl, MD</last_name>
      <phone>49-3641-9300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Leipold</last_name>
      <phone>49-721-974-3230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinderkrankenhaus Park Schoenfeld</name>
      <address>
        <city>Kassel</city>
        <zip>D-34121</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. L. Wright, MD</last_name>
      <phone>49-561-928-5108</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel</name>
      <address>
        <city>Kassel</city>
        <zip>D-34125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Rodehueser, MD</last_name>
      <phone>49-561-9800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein - Kiel Campus</name>
      <address>
        <city>Kiel</city>
        <zip>D-24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Claviez, MD</last_name>
      <phone>49-431-597-1620</phone>
      <email>a.claviez@pediatrics.uni-kiel.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Kemperhof Koblenz</name>
      <address>
        <city>Koblenz</city>
        <zip>D-56065</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Rister, MD</last_name>
      <phone>49-261-499-2602</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Krefeld GmbH</name>
      <address>
        <city>Krefeld</city>
        <zip>D-47805</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S. Volpel, MD</last_name>
      <phone>49-2151-322-375</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Annastift Krankenhaus</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67065</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Selle, MD</last_name>
      <phone>49-621-57021</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaets - Kinderklinik - Luebeck</name>
      <address>
        <city>Luebeck</city>
        <zip>D-23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter P. Bucsky, MD</last_name>
      <phone>49-451-500-2956</phone>
      <email>bucsky@paedia.ukl.mu-luebeck.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum der MA</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Mittler, MD</last_name>
      <phone>49-391-671-7210</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg University</name>
      <address>
        <city>Mainz</city>
        <zip>D-55101</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P. Gutjahr, MD</last_name>
      <phone>49-6131-172-112</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinik - Kinderklinik</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Duerken</last_name>
      <phone>49-621-383-2244</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaets - Kinderklinik</name>
      <address>
        <city>Marburg</city>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H. Christiansen, MD</last_name>
      <phone>49-6421-286-2650</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>D-32423</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W Tilmann, MD</last_name>
      <phone>49-571-801-4601</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>D-48129</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-251-834-7742</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Muenchen Schwabing</name>
      <address>
        <city>Munich</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Burdach, MD, PhD</last_name>
      <phone>49-89-3068-2276</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. von Haunersches Kinderspital der Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arndt Borkhardt</last_name>
      <phone>49-89-5160-2842</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen - Grosshadern Campus</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Schulz, MD</last_name>
      <phone>49-89-7095-2404</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Staedtisches Krankenhaus Muenchen - Harlaching</name>
      <address>
        <city>Munich</city>
        <zip>D-81545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-89-6210-2443</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Neubrandenburg</name>
      <address>
        <city>Neubrandenburg</city>
        <zip>17036</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H. J. Feickert, MD, PhD</last_name>
      <phone>49-395-775-2901</phone>
      <email>feickerthj@dbk-nb.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinderklinik Kohlhof</name>
      <address>
        <city>Neunkirchen</city>
        <zip>D-66539</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-681-3630</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cnopf'sche Kinderklinik</name>
      <address>
        <city>Nuremberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W. Scheurlen</last_name>
      <phone>49-911-334-002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hermann Mueller, MD</last_name>
      <phone>49-441-403-2013</phone>
      <email>mueller.hermann@klinikum-oldenburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik St. Hedwig-Kinderklinik</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ove Peters</last_name>
      <phone>49-941-3690</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinderklinik - Universitaetsklinikum Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>D-18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl Friedrich Classen, MD, PD</last_name>
      <phone>49-381-4940</phone>
      <email>carl-friedrich.classen@med.uni-rostock.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinderklink Siegen Deutsches Rotes Kreuz</name>
      <address>
        <city>Siegen</city>
        <zip>D-57072</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Burghard, MD</last_name>
      <phone>49-271-23450</phone>
      <email>rainer.burghard@drk-kinderklinik.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johanniter-Kinderklinik</name>
      <address>
        <city>St. Augustin</city>
        <zip>53757</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roswitha Dickerhoff, MD</last_name>
      <phone>49-2241-2490</phone>
      <email>roswitha.dickerhoft@uni-bonn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Olgahospital</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70176</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Bielack, MD</last_name>
      <phone>49-711-992-460</phone>
      <email>st.bielack@olgahospital.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenanstalt Mutterhaus der Borromaerinnen</name>
      <address>
        <city>Trier</city>
        <zip>D-54290</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Rauh, MD</last_name>
      <phone>49-651-947-2620</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaets-Kinderklinik</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72070</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-707-1298-3781</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupert Handgretinger, MD</last_name>
      <phone>49-7071-298-3781</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>D-89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus M. Debatin, MD</last_name>
      <phone>49-731-5002-7790</phone>
      <email>klaus-michael.debatin@medizin.uni-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reinhard-Nieter-Krankenhaus</name>
      <address>
        <city>Wilhelmshaven</city>
        <zip>D-26389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liebner, MD</last_name>
      <phone>49-4421-891-840</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaets - Kinderklinik Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>D-97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P. G. Schlegel, MD</last_name>
      <phone>49-931-2010</phone>
      <email>schlegel@mail.uni-wuerzburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Kliniken Wuppertal University Hospital</name>
      <address>
        <city>Wuppertal</city>
        <zip>D-42283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K. Sinha, MD</last_name>
      <phone>49-202-896-2441</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. Angst</last_name>
      <phone>49-41-628-384-941</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaets-Kinderspital beider Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Kuhne, MD</last_name>
      <phone>49-41-616-856-565</phone>
      <email>thomas.kuehne@ukbb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinderspital Luzern</name>
      <address>
        <city>Lucerne 16</city>
        <zip>CH-6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>U. Caflisch, MD</last_name>
      <phone>49-41-412-051-111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ostschweizer Kinderspital</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanette Greiner, MD</last_name>
      <phone>49-41-712-437-111</phone>
      <email>jeanette.greiner@kispisg.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Niggli, MD</last_name>
      <phone>49-41-1266-7111</phone>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2006</study_first_submitted>
  <study_first_submitted_qc>December 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2006</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <keyword>localized resectable neuroblastoma</keyword>
  <keyword>localized unresectable neuroblastoma</keyword>
  <keyword>regional neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
    <mesh_term>Vindesine</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

